알림

CSL Limited (CSLLY)

OTC Markets OTCQX: CSLLY · 실시간 가격 · USD

28.10

+4.15 (17.33%)

종가 기준: Aug 18, 2026, 3:56 PM

17.33% (1D)

매수호가	28.03
시가총액	53.83B
매출 (ttm)	n/a
순이익 (ttm)	n/a
베타	n/a
EPS (ttm)	-1.34
P/E (ttm)	n/a
선행 P/E	16.92
P/B (ttm)	2.90
P/S (ttm)	n/a
Earnings Date	Feb 9, 2027

매도호가	28.12
거래량	22,712
평균 거래량 (20일)	392,967
시가	28.16
전일 종가	23.95
일중 범위	27.92 - 28.16
52주 범위	16.01 - 37.90
애널리스트	n/a
목표주가	24.1 (-14.23%)
배당	$0.72 (2.58%)
배당락일	2026년 3월 11일

CSLLY 소개

CSL Limited engages in the research, development, manufacture, market, and distribution of biopharmaceutical products and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment manufactures, markets, and distributes plasma products, gene therapies, and recombinants. This segment...

[더 보기]

산업 Biotechnology

섹터 Healthcare

IPO 일자 Dec 29, 2009

직원 수 n/a

상장 거래소 OTC Markets OTCQX

티커 CSLLY

웹사이트 https://www.csl.com

전체 기업 정보

재무 실적

2025년 CSL의 매출은 15.43B로, 전년 14.69B 대비 5.04% 증가했습니다. 순이익은 3B로, 13.63% 증가했습니다.

재무제표

애널리스트 전망

애널리스트 1명의 투자의견을 종합하면 CSLLY 주식의 평균 등급은 "null"입니다. 12개월 목표주가는 24.1로, 최근 주가 대비 14.23% 하락 여력입니다.

주가 전망

다음 실적 발표

CSL Limited의 실적 발표 예정일은 Feb 9, 2027, 정규장 중입니다.
애널리스트 예상 매출은 ... 업그레이드

뉴스

3주 전 · Investing.com

Australia to challenge Trump’s new 12.5% tariff, says PM Albanese

Investing.com -- Australian Prime Minister Anthony Albanese said he would raise Washington’s new 12.5% tariff on Australian goods directly with U.S. President Donald Trump, Reuters reported.

1개월 전 · The Wall Street Journal

European Regulator Calls for Amgen’s Tavneos to Have Authorization Revoked

The committee is recommending that no new patients start treatment with Tavneos and that existing patients be switched to suitable alternatives.

2개월 전 · Proactive

Imugene strengthens board with biotech and pharma appointments

Imugene Ltd (ASX:IMU, OTC:IUGNF, FRA:ILA) has appointed Dr Charmaine Gittleson and Michael Kotsanis as non-executive directors as part of a board enhancement process aimed at supporting the company’s ...

3개월 전 · Simply Wall St.

3 ASX Dividend Stocks Yielding Up To 4.2%

As the Australian market grapples with global uncertainties and fluctuating commodity prices, investors are increasingly seeking stability amidst the volatility. In such an environment, dividend stock...

3개월 전 · GuruFocus.com

CSL Plunges 22% After Cutting Outlook And Flagging $5 Billion Impairments

CSL now expects weaker full-year revenue and profit as plasma, China pricing, and Vifor pressures weigh on performance.

2 페이지 중 1

CSL Limited (CSLLY)

CSLLY 소개

재무 실적

애널리스트 전망